Detalles de la búsqueda
1.
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
N Engl J Med
; 2024 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38828946
2.
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
Lancet Oncol
; 25(1): 46-61, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38101431
3.
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN study.
Future Oncol
; 20(10): 563-578, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38126311
4.
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(9): 989-1001, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37591293
5.
Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study.
Cancer
; 129(1): 118-129, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36308296
6.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32997907
7.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med
; 383(24): 2345-2357, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32955174
8.
Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium.
Urol Int
; 107(6): 595-601, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36996793
9.
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Lancet
; 397(10274): 592-604, 2021 02 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33581821
10.
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
N Engl J Med
; 381(1): 13-24, 2019 07 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31150574
11.
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Gastric Cancer
; 25(3): 586-597, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34997449
12.
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial.
Gastric Cancer
; 25(1): 197-206, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34468869
13.
Comparison of iodine-125 plaque brachytherapy and gamma knife stereotactic radiosurgery treatment outcomes for uveal melanoma patients.
Graefes Arch Clin Exp Ophthalmol
; 260(4): 1337-1343, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34735632
14.
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(7): 931-945, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34051178
15.
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 22(1): 51-65, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33285097
16.
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10236): 1547-1557, 2020 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416780
17.
A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience.
Oncologist
; 26(5): e769-e779, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687747
18.
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
N Engl J Med
; 379(24): 2342-2350, 2018 12 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30280658
19.
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
J Urol
; 206(4): 914-923, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34039013
20.
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Gastric Cancer
; 24(6): 1330-1340, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34363528